Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Executive Summary
Approval of Wyeth/Aviron's intranasal flu vaccine FluMist will likely hinge on further analysis of the pulmonary safety data for the product and information about interactions with concurrent immunizations following a review by FDA's Vaccines & Related Biological Products Advisory Committee July 27.
You may also be interested in...
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
MedImmune expects pharmacists in 36 states to administer FluMist to patients upon launch of the intranasal flu vaccine, President Melvin Booth said